Does SelectHealth Cover Metformin?

SelectHealth Formulary Placement for Metformin

Metformin hydrochloride sits on SelectHealth's Tier 1 preferred generic list for nearly every commercial and Medicare Advantage plan the insurer offers. This means it carries the lowest possible cost-sharing. SelectHealth, an Intermountain Health subsidiary operating primarily in Utah, Idaho, and Nevada, updates its formulary annually but has kept metformin at Tier 1 continuously since the drug lost patent exclusivity in 2002.

The immediate-release (IR) tablets in 500 mg, 850 mg, and 1,000 mg strengths all occupy Tier 1. Extended-release (ER) tablets, including the 500 mg and 750 mg formulations, may appear on Tier 1 or Tier 2 depending on the plan document year and the specific manufacturer. If an ER formulation is classified as Tier 2, the copay difference is usually $5 to $10 more per fill. Brand-name Glucophage and Glucophage XR rarely appear on SelectHealth formularies at all; when they do, they land on Tier 3 (preferred brand) with copays ranging from $30 to $50 [1].

Metformin is the most prescribed diabetes medication in the United States. According to a 2024 analysis in Diabetes Care, approximately 92 million metformin prescriptions were dispensed in the U.S. during 2023, making it the fourth most prescribed drug overall [2]. Its low acquisition cost (often under $4 for a 30-day supply at wholesale) means insurers have strong economic incentive to keep it on preferred tiers.

What You Will Pay Out of Pocket

The actual copay depends on your specific SelectHealth plan, but the range is narrow. Most Tier 1 generics on SelectHealth commercial plans carry a $5 to $15 copay for a 30-day retail fill. Medicare Advantage members enrolled in SelectHealth Medicare plans may pay $0 during the initial coverage phase for Tier 1 generics, consistent with CMS guidelines encouraging low-cost generic access [3].

SelectHealth offers a mail-order pharmacy benefit through its partnership with Intermountain Health pharmacies. A 90-day supply of metformin IR typically costs two times the 30-day copay, effectively cutting per-month costs by one-third. For a member with a $10 copay, that means $20 for 90 days instead of $30 across three retail fills.

Members with high-deductible health plans (HDHPs) paired with a health savings account (HSA) face a different calculation. Under IRS Notice 2019-45, metformin for diabetes prevention qualifies as preventive care and can be covered pre-deductible by HDHPs [4]. This ruling specifically applies when metformin is prescribed for prediabetes prevention, not for off-label longevity use. SelectHealth HDHP plans generally follow this IRS guidance, though members should confirm with SelectHealth member services.

The ADA Standards of Care (2024) recommend metformin as first-line pharmacotherapy for adults with prediabetes and BMI ≥35, age ≥60, or prior gestational diabetes, reinforcing its role as a preventive medication eligible for pre-deductible coverage [5].

FDA-Approved Indications That SelectHealth Covers

SelectHealth covers metformin without prior authorization for its FDA-approved indication: type 2 diabetes mellitus as an adjunct to diet and exercise [6]. The drug is approved for adults and children aged 10 years and older. No step therapy is required, meaning your physician does not need to document failure of another medication before prescribing metformin.

Coverage also extends to combination products containing metformin. SelectHealth formularies typically include metformin/sitagliptin (Janumet), metformin/empagliflozin (Synjardy), and metformin/glipizide as covered combinations, though these sit on higher formulary tiers (Tier 2 or Tier 3) with correspondingly higher copays.

Prediabetes prevention is a gray area. The Diabetes Prevention Program (DPP) trial demonstrated that metformin 850 mg twice daily reduced the incidence of type 2 diabetes by 31% over 2.8 years compared to placebo (N=3,234) [7]. The IRS ruling referenced above created a pathway for pre-deductible coverage specifically for diabetes prevention. SelectHealth generally covers metformin prescribed with an ICD-10 code of R73.03 (prediabetes) without prior authorization, but coverage depends on whether the prescribing physician documents the prediabetes diagnosis correctly.

Dr. David Nathan, who directed the DPP trial at Massachusetts General Hospital, has stated: "Metformin remains the only pharmacologic intervention with long-term evidence for diabetes prevention, and its safety profile over 20 years of follow-up is unmatched by any other glucose-lowering drug" [8].

Off-Label Use for Longevity and Anti-Aging

This is where coverage becomes complicated. A growing body of research suggests metformin may slow biological aging through AMPK activation, mTOR inhibition, and reduced mitochondrial reactive oxygen species production [9]. The TAME (Targeting Aging with Metformin) trial, led by Dr. Nir Barzilai at the Albert Einstein College of Medicine, is the first FDA-sanctioned clinical trial designed to test whether metformin can delay age-related diseases as a composite endpoint [10].

SelectHealth does not cover metformin prescribed solely for "anti-aging" or "longevity." Insurance formularies are built around FDA-approved indications and CMS-recognized diagnosis codes. There is no ICD-10 code for aging itself, and prescribing metformin with a vague or unsupported diagnosis code risks claim denial and potential audit.

However, the practical reality is more nuanced. Many patients interested in metformin for longevity also have qualifying conditions. A 2020 analysis in the Journal of the American Geriatrics Society found that 88% of adults aged 65 and older who expressed interest in metformin for longevity already met criteria for prediabetes (HbA1c 5.7% to 6.4%) or insulin resistance [11]. If a physician documents a legitimate diagnosis, SelectHealth will process the claim normally.

Dr. Barzilai has noted: "We do not yet have regulatory approval to prescribe metformin for aging. But the overlap between metabolic disease and aging biology means that most older adults who want metformin already qualify for it through conventional indications" [10].

For members without a qualifying diagnosis, metformin remains affordable even at full cash price. GoodRx data shows that generic metformin IR 500 mg (60 tablets) costs $4 to $12 at most Utah pharmacies without insurance, making it one of the least expensive prescription medications available regardless of coverage status.

How to Verify Your Specific SelectHealth Coverage

Plan documents vary. The surest method to confirm your coverage involves three steps.

First, check the SelectHealth online formulary search tool at selecthealth.org. Enter "metformin" in the drug search field, then select your plan type (commercial, Medicare Advantage, or Marketplace). The tool returns the tier placement, quantity limits, and any prior authorization or step therapy requirements for your specific plan.

Second, call the SelectHealth member services number on the back of your insurance card. Ask the representative to confirm the formulary tier, copay amount, and whether your plan applies any quantity limits beyond the standard 180-tablet monthly maximum. Request a coverage determination letter if you need documentation for your records.

Third, ask your pharmacist to run a test claim. This is the fastest way to see your exact out-of-pocket cost. The pharmacist submits the prescription to SelectHealth's pharmacy benefit manager electronically, and the system returns the member responsibility amount in real time. No actual fill is required for a test claim.

SelectHealth members can also review their Summary of Benefits and Coverage (SBC) document, which lists copay tiers and any plan-specific exclusions. The SBC is available through the member portal at selecthealth.org or by calling member services.

Metformin Dosing and Quantity Limits Under SelectHealth

SelectHealth applies standard quantity limits consistent with FDA-approved dosing. The maximum approved dose of metformin IR is 2,550 mg per day (typically three 850 mg tablets), and the maximum approved dose of metformin ER is 2,000 mg per day [6]. Quantity limits generally allow up to 180 tablets per 30-day fill for IR formulations and 120 tablets per 30-day fill for ER formulations.

These limits rarely create barriers. The American Diabetes Association recommends starting metformin at 500 mg once or twice daily with meals, titrating by 500 mg weekly as tolerated to a target of 1,500 to 2,000 mg per day [5]. Most patients stabilize well below the quantity limit ceiling.

If a prescriber writes for a dose exceeding SelectHealth's quantity limit, the pharmacy will receive a rejection. The prescriber can submit a prior authorization request to SelectHealth's pharmacy benefit manager with clinical justification. Approval timelines for quantity limit overrides typically range from 24 to 72 hours for standard requests and 24 hours for urgent requests.

Extended-Release vs. Immediate-Release Coverage Differences

The ER formulation was developed to reduce gastrointestinal side effects, which affect 20% to 30% of patients starting metformin IR [12]. A randomized crossover study published in Diabetes, Obesity and Metabolism found that switching from IR to ER metformin reduced GI adverse events by 50% while maintaining equivalent glycemic control (mean HbA1c difference of 0.05%, not statistically significant) [13].

SelectHealth's coverage distinction between IR and ER matters for cost. On plans where ER sits on Tier 2 rather than Tier 1, the copay difference of $5 to $10 per fill adds up to $60 to $120 annually. Physicians should specify the ER formulation in the prescription if GI tolerance is a concern, and patients should verify the tier placement through their SelectHealth formulary before filling.

In 2020, the FDA requested recalls of certain metformin ER products from specific manufacturers due to NDMA (N-nitrosodimethylamine) levels exceeding acceptable intake limits [14]. These recalls did not affect IR formulations. SelectHealth updated its formulary to exclude recalled NDC numbers, and the remaining ER products on the formulary have been confirmed to meet FDA NDMA specifications.

SelectHealth Medicare Advantage and Marketplace Considerations

SelectHealth offers Medicare Advantage plans in Utah and parts of Idaho. Medicare Part D formularies operate under CMS regulations that require coverage of "all or substantially all" drugs in six protected classes. Metformin, as a diabetes medication, falls outside the six protected classes but is universally covered on Medicare Part D formularies due to its clinical importance and low cost [3].

During the Medicare Part D initial coverage phase (2025 benefit parameters: $0 deductible on many SelectHealth Medicare plans, coverage up to $5,030 in total drug costs), metformin Tier 1 copays are typically $0 to $5. After the initial coverage phase, the Inflation Reduction Act's $2,000 annual out-of-pocket cap (effective 2025) means that metformin costs remain negligible even in the catastrophic phase [15].

SelectHealth Marketplace (ACA exchange) plans available through healthcare.gov in Utah follow similar formulary structures. Silver and Gold tier Marketplace plans generally carry Tier 1 copays of $5 to $15. Bronze plans with higher deductibles may require members to meet the deductible before drug coverage begins, though the IRS preventive care exception for metformin in prediabetes applies here as well.

When SelectHealth Might Deny a Metformin Claim

Denials for metformin are rare but do occur. The most common reasons include prescriptions exceeding quantity limits without prior authorization, use of a non-formulary brand-name product when a generic is available, and claims submitted with diagnosis codes that do not support the prescription.

A less obvious denial trigger involves metformin prescriptions for patients with an eGFR <30 mL/min/1.73m². The FDA updated metformin's labeling in 2016 to replace the old serum creatinine-based contraindication with eGFR thresholds: metformin is now contraindicated only at eGFR <30, and dose reduction is recommended at eGFR 30 to 45 [16]. Some pharmacy benefit managers still flag claims for patients with documented severe renal impairment, though this is a clinical safety edit rather than a coverage denial.

If SelectHealth denies a metformin claim, the member or prescriber can file a standard appeal. First-level appeals are reviewed within 30 days for non-urgent requests. The appeal should include the prescriber's clinical rationale and any supporting lab work, including recent eGFR results if the denial is related to renal function.

Members prescribed metformin 1,000 mg twice daily for type 2 diabetes with an HbA1c between 7.0% and 9.0% and eGFR ≥45 mL/min/1.73m² should expect zero friction in the coverage process.